Sygnature Discovery, an integrated drug discovery contract research organisation (CRO), has announced the completion of a £1 million enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure. The investment has resulted in a doubling of synthesis and purification capacity,
Evestia Clinical has announced a merger with US-based Atlantic Research Group (ARG), forming an enlarged global CRO group with expanded capabilities across therapeutic areas and clinical development phases. The merger, which more than doubles the size of the Group by
Momentum Biotechnologies has successfully acquired OmicScouts GmbH, a contract research organisation (CRO) based in Munich, Germany. The move strengthens Momentum’s position in mass spectrometry-based drug discovery and enables geographic expansion into the European market. OmicScouts will continue operations under its new name, OmicScouts,
AbbVie has announced a licensing agreement with Gubra to develop and commercialize GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. The agreement marks AbbVie’s entry into the obesity market, an area of growing pharmaceutical focus. GUB014295, currently in a
Emmes Group, a specialty technology and AI-enabled contract research organisation (CRO), has been accredited with ISO/IEC 27001:2022 certification. The certification follows a comprehensive audit, validating the company’s adherence to global information security standards across its people, processes, and technology. The
Kenox Pharmaceuticals Inc. has expanded its drug development services by introducing small-scale non-sterile GMP capabilities to support GLP preclinical studies. The company, focused on Orally Inhaled and Nasal Drug Products (OINDPs), aims to accelerate drug development by providing a streamlined
Diverchim, a renowned French Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Innoverda, a Contract Research Organization (CRO) known for its electrochemical process solutions. The deal merges Diverchim’s strengths in drug substance development with Innoverda’s expertise in
XingImaging, a MITRO company, has expanded its operations with the opening of a new, state-of-the-art research facility in New Haven, Connecticut. The new site, which became fully operational on 17 November 2024, includes advanced clinical research capabilities, cGMP radiochemistry laboratories,
Biofidelity, a company specialising in innovative genomic solutions, has partnered with CellCarta, a global contract research organisation (CRO), to integrate the Aspyre Lung platform into clinical trials worldwide. The partnership seeks to enhance the detection of NSCLC biomarkers, expediting clinical
Phastar, a global biometrics contract research organisation (CRO), has been named the Best CRO – Specialist Providers at the 2024 Scrip Awards. The award ceremony took place on December 4th at Raffles London at the OWO, celebrating the company’s specialised
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
